Glatiramer acetate (Copaxone) for Clinically Isolated Syndrome – PBAC Review

7 June 2017

Medication Subsidy (PBAC)
Category
Category
year
Year

MS Australia Submissions

23 April 2026

MS Australia’s submission to the Inquiry into the Integrity of the NDIS highlights widespread risks of fraud and non-compliance, particularly among unregistered providers, leading to harm, reduced supports, and loss of trust for participants. It recommends compulsory provider and worker registration (with limited exemptions), stronger safeguards, improved transparency, and tailored approaches for rural areas and self-management to better protect participants and strengthen scheme integrity.

4 March 2026

MS Australia’s submission to the NDIA raises significant concerns about the NDIS proposed new framework planning rules. MS Australia calls for delayed implementation to allow for genuine co‑design, better staff training, participant review of draft support need assessments, removal of informal supports in NDIS plan budgeting, and clear, accessible guidance.

5 February 2026

MS Australia’s submission to the 2025–26 NDIS Annual Pricing Review highlights that current NDIS pricing is inconsistent, inflexible and fails to reflect the real cost of supporting people with progressive neurological conditions. The submission recommends differentiated and sustainable pricing, removal of quarterly funding periods, increased prices for therapy, support coordination, plan management and registered providers, and transferring pricing responsibility to IHACPA to ensure transparent, evidence‑based and independent pricing across the sector.

2 February 2026

MS Australia’s 2026–27 Pre‑Budget Submission seeks investment to address rising MS prevalence and growing economic impacts. It calls for funding to expand MS research and data infrastructure, increase access to MS Nurses, improve NDIS pricing and planning, strengthen the disability and aged care workforce, and ensure equitable supports for older people with disability. The submission outlines four priority areas: research, nursing, disability reform, and aged care system improvements.

30 January 2026

MS Australia’s submission to the inquiry highlights systemic issues in NDIS administration, including inconsistent claims management, inadequate pricing, delayed payments, and disproportionate compliance burdens on registered providers. It calls for clearer pre‑payment rules, risk‑based compliance, improved performance reporting, and a tiered regulatory model. The submission urges the Department to recognise gaps between policy and practice, strengthen two‑way consultation, and address sudden operational changes impacting people with MS and service providers.
Read More

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

Glatiramer acetate (Copaxone) for Clinically Isolated Syndrome – PBAC Review